$15.88
-0.26-1.61%
Last update: Nov 11, 8:54 AM
Nurix Therapeutics Inc
NRIXNASDAQ
Nurix Therapeutics rose 23.5% from $12.86 to $15.88, ahead of the S&P 500's +9.8%. Its worst day was Nov 4 (−38.2%), and its low came Nov 12 at $12.17.
Nov 11, 2025 – Nov 10, 2026 · picked from earnings, analyst actions, headlines and the biggest daily moves
Nurix Therapeutics closed at its lowest level of the year, 5.4% below where the year started.
−5.4% · S&P 500 +0.1%
Story events cover the past 12 months · Times ET
Objective response rate (ORR) of 83% including two complete responses in CLL patients in Phase 1a study with median progression free survival (PFS) of 22.1 months across all doses testedEmerging data from randomized
+18.7%, the year's best day · S&P 500 −0.3%
EPS of $-0.82 beat the $-0.89 estimate on $13.6M revenue (est. $15.2M).
−1.6% · S&P 500 −0.2%
EPS of $-0.79 missed the $-0.76 estimate on $6.3M revenue (est. $14.4M).
−4.6% · S&P 500 +2.5%
Nurix Therapeutics shares rose 11.0%, while the S&P 500 rose 1.7%.
+11.0% · S&P 500 +1.7%
Nurix Therapeutics shares rose 16.4%, while the S&P 500 rose 0.1%.
+16.4% · S&P 500 +0.1%
EPS of $-0.81 missed the $-0.72 estimate on $9.0M revenue (est. $15.1M).
−6.6% · S&P 500 +0.4%
Nurix Therapeutics closed at its highest level of the year, 116.1% above where the year started.
+3.2% · S&P 500 +0.2%
EPS of $4.73 beat the $3.98 estimate on $673.1M revenue (est. $411.5M).
−0.1% · S&P 500 0.0%
Nurix Therapeutics shares fell 38.2%, while the S&P 500 rose 1.7%.
−38.2%, the year's worst day · S&P 500 +1.7%
Where it ended: a close of $15.88 on Nov 10, 2026. Up next: Q4 2026 earnings on Jan 27, 2027 (EPS est. $1.11, revenue est. $235.4M).
Nothing in the past 12 months.
All NRIX dividend historyReplay the year: the line draws itself and stops at each of the 10 moments with what happened and how the stock reacted.
Chart by ChartIQ. Events, ratings, quote and fundamentals from Benzinga APIs. Daily bars for NRIX and SPY from Benzinga historical bars. Not investment advice.
